By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cell Signaling Technology today announced it has licensed its patent rights and proprietary antibody reagents related to the detection of epidermal growth factor receptor mutations to Ventana Medical Systems.

The non-exclusive licensing agreement is for the field of tissue-based in vitro diagnostics testing, the Danvers, Mass.-based antibody firm said. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.